Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Global Blood Therapeutics, Inc. - Common Stock (NQ: GBT )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) 68.47 (25)
Ask (Size) 68.49 (90)
Prev. Close 68.49
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding 67,463,704
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022
We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022. 
Via Talk Markets

Performance

More News

Read More
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
Via Investor's Business Daily
Global Blood Therapeutics's Return On Capital Employed Overview
Via Benzinga
Where Global Blood Therapeutics Stands With Analysts
Via Benzinga
Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics
Via Investor's Business Daily
Pfizer Scoops Up Sickle Disease Player For $5B
Via Benzinga
Global Blood Therapeutics's Return On Capital Employed Overview
Via Benzinga
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal
Via Benzinga
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
From Kahn Swick & Foti, LLC
Via Business Wire
10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others
Via Investor's Business Daily
Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million
Via Investor's Business Daily
Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review
Via Investor's Business Daily
Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US
Via Benzinga
8 Analysts Have This to Say About Global Blood Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022
Via Benzinga
Global Blood Therapeutics: Q2 Earnings Insights
Via Benzinga
GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT
From Kahn Swick & Foti, LLC
Via Business Wire
Why These Pfizer Analysts Like The Global Blood Therapeutics Deal
Via Benzinga
TBLT, RDBX: The Top 5 Short Squeeze Stocks to Watch This Week
Via InvestorPlace
GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022
Via Benzinga
Global Blood (GBT) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Global Blood Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GBT
From Halper Sadeh LLP
Via Business Wire
Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8
Via Benzinga
iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.